Drug Profile
RU 52583
Latest Information Update: 22 Nov 1999
Price :
$50
*
At a glance
- Originator Aventis
- Class Antidementias; Antidepressants; Neuroprotectants
- Mechanism of Action Alpha 2 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 22 Nov 1999 No-Development-Reported for Cognition disorders in France (Unknown route)
- 18 Jul 1996 Phase-I clinical trials for Cognition disorders in France (Unknown route)